In response to an ever-growing US client base, Selcia today announced the opening of their new SelciaWest facility, in Hopkinton MA (USA).
Ongar, Essex, United Kingdom (22 August 2011). In response to an ever-growing US client base, Selcia today announced the opening of their new SelciaWest facility, in Hopkinton MA (USA).
Simon Saxby, Selcia’s CEO, commented on the opening: “The establishment of a dedicated base in the US is a demonstration of our commitment to provide our clients and collaborators in North America with the highest level of service and attention, combined with “best in class” science, for which Selcia is globally recognised”.
The Hopkinton facility will initially focus on providing Selcia’s proprietary CEfrag™ fragment screening service for the company’s global pharma/biotech clients.
Selcia Limited is a leading provider of contract research services in 14-C custom radiolabelling, integrated drug discovery, fragment screening and medicinal chemistry. Selcia operate from 2,800sqm modern facilities with a GLP analytical laboratory, in Ongar, Essex, United Kingdom and Hopkinton, MA, USA.
Selcia’s Discovery division provides integrated drug discovery services to the pharmaceutical and biotechnology industries; these services include medicinal, organic and analytical chemistry, molecular modelling, in vitro biological screening, fragment screening and in vitro ADME/PK evaluation as well as in vivo PK (with a strategic partner). Selcia’s scientists act as integrated project teams within the customer group striving to produce viable drug candidates against its partners’ biological targets. Selcia’s capillary electrophoresis screening platform offers unique opportunities for biological screening of many important target classes. Its proprietary fragment screening service, CEfrag™, is a powerful application of the technique at the outset of a drug discovery programme. CEFrag™ was nominated for ‘Killer Technology’ in the 2010 East of England Business Awards.
Selcia’s Radiolabelling division is a proven leader in delivering pure radiolabelled compounds for preclinical and clinical ADME studies.
T: +44 (0) 1179 739224
T: +44 (0) 1277 367000